Insulin Treatment Inhibits PAI-1 Production in NIDDM Patients with Endothelial Dysfunction

Abstract

We examined 34 non-insulin-dependent diabetes mellitus (NIDDM) patients treated with sulfonylurea regimens, 24 NIDDM patients with 2-3 months long-acting insulin treat ment and 19 age-matched normoinsulinemic healthy controls. NIDDM patients were divided into two subgroups, with and without endothelial dysfunction according to von Willebrand factor level 0.14 IU/mL. There were significant differences in PAI-1 levels among patients without endothelial dysfunction treated by sulfonylurea agents (median 48.1, range 14-108 ng/ mL) or insulin (27.9, 2-53 ng/mL) and patients with endothe lial dysfunction treated by sulfonylurea regimens (80.7, 43-217 ng/mL) or insulin, respectively, (16.7, 7-34 ng/mL) (analysis of variance p < .001). NIDDM subgroups were not different in metabolic parameters (C-peptide and triglyceride levels, body mass index) and platelet activation marker (platelet factor 4 values). von Willebrand Factor and thrombomodulin levels were elevated in groups with endothelial dysfunction (analysis of variance p < .001, p = .025, respectively). Insulin treatment was accompanied by decreased PAI-1 levels especially in pa tients with endothelial dysfunction. Insulin is the inhibitor of endothelial PAI-1 production induced by cytokines. Therefore, we suggest that long-term insulin application may decrease PAI-1 levels by direct inhibitive action on the endothelial PAI-1 compartment. This hypothesis requires further research.

Keywords

Key Words: Plasminogen activator inhibitor type 1 Insulin treatment Non-insulin-dependent diabetes mellitus Endothelial dysfunction.

Get full access to this article

View all access options for this article.

References

Alessi MC , Juhan-Vague I. , Kooistra T. , et al. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by hepatocellular cell line HepG2. Thromb Haemost 1988;60:491.

Alessi MC , Peiretti F. , Morange P. , et al. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease . Diabetes 1997;46:860.

Hamsten A. , Eriksson P. Fibrinolysis and atherosclerosis: an update. Fibrinolysis 1994;8:253.

Juhan-Vague I. , Alessi MC , Vague P. Increased plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis . Diabetologia 1991 ;34:457.

Juhan-Vague I. , Alessi MC PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997 ;78:656.

Vague P. , Juhan-Vague I. , Aillaud MF , et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism 1986 ;35:250.

Wiman B. Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995;74:71.

Marckmann P. Diet, blood coagulation and fibrinolysis . Dan Med Bull 1995;42:410.

Galajda P. , Martinka E. , Staško J. , et al. Plasminogen activator inhibitor type-1 (PAI-1) levels are decreased in NIDDM patients treated by insulin. Clin Appl Thromb Hemost (in press).

10.

Yamauchi K. , Shigematsu S. , Nakajima K. , et al. Insulin differentially modified TGFβ action in blood vessel cells. Diabetes 1997 ; 46:388A.

11.

Blann AD , Taberner DA

A reliable marker of endothelial cell dysfunction: does it exist?

Br J Haematol 1995;90:244.

12.

Galajda P. , Martinka E. , Mokáň M. , Kubisz P. Endothelial markers in diabetes mellitus. Thromb Res 1997;85:63.

13.

Jern C. , Seeman-Lodding H. , Biber B. , et al. An experimental multiple-organ model for the study of regional net release/uptake rates of tissue-type plasminogen activator in the intact pig. Thromb Haemost 1997;78:1150.